Price
Target price
-
-
-
-
-
?14.66
WKN: A2P26W / Symbol: CYCC / Name: Cyclacel Pharmaceuticals Inc. / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cyclacel Pharmaceuticals Inc. Stock
The sentiment is rather negative at the moment with 12 Sell predictions and 2 Buy predictions.
However, we have a potential of 6263.64% for Cyclacel Pharmaceuticals Inc. as the target price of 14 € is above the current price of 0.22 €.
For the coming years our community has positive and negative things to say abot the Cyclacel Pharmaceuticals Inc. stock. Criterium "EBIT Margin" gathered the most positive votes but regarding "Expected Cash Flow" there were negative voices in the community.
Pros and Cons of Cyclacel Pharmaceuticals Inc. in the next few years
Pros
?
S********** s********
?
B****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cyclacel Pharmaceuticals Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Cyclacel Pharmaceuticals Inc. | - | - | - | - | - | - | - |
Vaxart Inc. | -1.640% | -2.530% | -29.984% | -29.128% | 27.036% | -87.843% | - |
Larimar Therapeutics Inc. | -0.680% | 5.072% | 14.173% | 62.556% | 77.696% | -33.486% | -73.588% |
Jaguar Health Inc. | -4.190% | -8.209% | 152.661% | -58.687% | 79.205% | -99.886% | - |
Comments
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) had its price target lowered by analysts at Roth Mkm from $21.00 to $11.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat